RARE - Ultragenyx Pharmaceutical Inc.

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Ultragenyx Pharmaceutical GAAP EPS of -$2.33 misses by $0.33, revenue of $100.5M misses by $3.4M
• Ultragenyx Pharmaceutical Q1 2023 Earnings Preview
• Ultragenyx a new Overweight at Cantor after recent selloff
• Regeneron gets FDA approval for expanded use of high cholesterol drug Evkeeza in kids
• Ultragenyx appoints Eric Crombez Chief Medical Officer and executive Vice President
• Ultragenyx Pharmaceutical GAAP EPS of -$2.16 beats by $0.02, revenue of $103.35M misses by $1.76M
• Ultragenyx Pharmaceutical Q4 2022 Earnings Preview
• Stocks 'disconnected from reality'; Morgan Stanley screens those 'unfairly punished'
• Ultragenyx sees 2023 product revenue of $425M-$450M
• Ultragenyx Pharmaceutical CFO Mardi Dier to step down
• Ultragenyx Pharmaceutical GAAP EPS of -$3.50 misses by $1.66, revenue of $90.7M misses by $5M
• Ultragenyx Pharmaceutical Q3 2022 Earnings Preview
• Ultragenyx upgraded to buy at Guggenheim as stock trading at discount to biotech peers
• Ultragenyx grants stock options, restricted stock units
• Ultragenyx downgraded to in line at Evercore on 'noise' regarding Angelman candidate
• Ultragenyx Pharmaceutical GAAP EPS of -$2.26 misses by $0.49, revenue of $89.34M beats by $2.01M
• Ultragenyx Pharmaceutical Q2 2022 Earnings Preview
• Ultragenyx down 13% following acquisition of Angelman syndrome biotech
• Ultragenyx to acquire GeneTx after promising data on Angelman syndrome treatment
• Ultragenyx sells part of North American royalties on Crysvita to OMERS for $500M